17% of USFDA Inspections at Indian Drug Plants Flag Serious Lapses, Ind-Ra Warns of Risk to US Growth
About 17% of USFDA inspections at Indian pharma facilities now end with an Official Action Indicated classification, up from 11% in 2024, India Ratings says, warning that tougher scrutiny could delay approvals as US sales of Indian drugmakers soften.
